Replies to post #72 on Affimed NV (AFMD)

[onin2downin2]

Thanks for an informative and interesting hour.

I know very little about anything, but my ignorance of Biology was no barrier to slipstreaming Genentec in buying a small amount of Affimed.

Betting on their analysis, I figured $5 billion a reasonable valuation.

Juno Therapeutics had similar issues, but was ultimately acquired by Celgene for $9 billion.

They settled for $24 million in a class action for not immediately disclosing 3 deaths in a trial.